title: Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood in vitro.
abstract: We analyzed the in vitro effects of sorbitol and fructose on platelet function. Sorbitol and fructose increased platelet aggregation induced with adenosine diphosphate (ADP) or collagen in whole blood, but had no effect in platelet-rich plasma. The concentration that increased basal aggregation by 50% with ADP as the inducer was 12.89 +/- 1.55 mmol/L for fructose, and 18.99 +/- 2.01 mmol/L for sorbitol. When collagen was the inducer, these concentrations were 15.02 +/- 0.98 mmol/L for fructose, and 12.94 +/- 1.57 mmol/L for sorbitol. Both sugars increased, in a concentration-dependent way, the proaggregatory effect of erythrocytes, and erythrocyte uptake of adenosine. Time to uptake of 50% adenosine was 2.1 +/- 0.3 min in control samples, 0.14 +/- 0.01 min in the presence of fructose, and 0.23 +/- 0.03 min with sorbitol. Both sugars reduced vascular prostacyclin synthesis, with 50% inhibitory concentrations of 26.48 +/- 1.97 mmol/L for fructose, and 39.53 +/- 2.81 mmol/L for sorbitol. Both sugars also increased arterial lipid peroxidation by 30% (sorbitol) and 23% (fructose). We conclude that these two sugars enhance platelet function and disrupt the thromboxane/prostacyclin ratio.
authors.affiliation: Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Spain.
authors.forename: J P
authors.initials: JP
authors.lastname: De la Cruz
authors.forename: M A
authors.initials: MA
authors.lastname: Maximo
authors.forename: E
authors.initials: E
authors.lastname: Blanco
authors.forename: A
authors.initials: A
authors.lastname: Moreno
authors.forename: F
authors.initials: F
authors.lastname: Sánchez de la Cuesta
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000241:Adenosine / Q000097:blood; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D000818:Animals; D001011:Aorta / Q000187:drug effects / Q000378:metabolism; D001786:Blood Glucose / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D003094:Collagen / Q000494:pharmacology; D003925:Diabetic Angiopathies / Q000097:blood / Q000209:etiology; D011464:Epoprostenol / Q000096:biosynthesis* / Q000097:blood; D004912:Erythrocytes / Q000378:metabolism*; D005632:Fructose / Q000494:pharmacology*; D006801:Humans; D006943:Hyperglycemia / Q000097:blood; D066298:In Vitro Techniques; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D015539:Platelet Activation / Q000187:drug effects* / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar; D013012:Sorbitol / Q000494:pharmacology*; D013929:Thromboxane B2 / Q000096:biosynthesis
chemical_list: D001786:Blood Glucose; D005632:Fructose; D013012:Sorbitol; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000244:Adenosine Diphosphate; D003094:Collagen; D011464:Epoprostenol; D000241:Adenosine